Myelofibrosis is a serious bone marrow disorder that disrupts your body's normal production of blood cells. The result is extensive scarring in your bone marrow, leading to severe anemia, weakness, fatigue, and often, an enlarged spleen and liver. Myelofibrosis is an uncommon type of chronic leukemia — a cancer that affects the blood-forming tissues in the body. Myelofibrosis belongs to a group of diseases called myeloproliferative disorders.
In 2008, the World Health Organization expanded the classification of myeloproliferative disorders based on increasing amounts of molecular and cytogenetic data. Myeloproliferative neoplasms (MPN) that do not contain the BCR-ABL1 mutation include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). JAK2V617F is the best characterized mutation in BCR-ABL1-negative neoplasms, with an estimated prevalence of more than 95% in PV, 50% in ET, and 50% in PMF.
In the past, the treatment of myelofibrosis has depended on the symptoms and degree of the low blood counts. A long-term remission is possible for some patients with bone marrow transplantation. Such treatment should be considered for younger patients and some others. Other treatment may involve:Blood transfusions and medicines to correct anemia, Radiation and chemotherapy, Medicines to target a genetic mutation, Splenectomy if swelling causes symptoms, or to help with anemia.